| Name | Title | Contact Details |
|---|
At Prospero, we believe a person`s care should be determined by preference, not dictated by their medical condition. That`s why we are building a new kind of healthcare company, providing loving care and support for a growing population of people and their families facing serious illness. The rising challenge for people and their families, the healthcare system, and our country is significant, and that`s why we must meet it head on by hiring the best people with a heart for service. At Prospero, we empower people to live their best lives now with loving and compassionate home-based care and support.
CME was founded in 1978 by psychiatrist John Schwartz, whose vision was to provide high-quality, practical continuing medical education and information for mental health clinicians throughout the United States. In its first decade, CME successfully
The Warner Babcock Institute for Green Chemistry is dedicated to the development of non toxic, environmentally benign and sustainable technological solutions for society. Focused on the practical application of Green Chemistry, we assist our industry partners in the development of sustainable technologies, products, and processes at the molecular level. Our emphasis is on the practical application of Green Chemistry concepts to drive cost savings and minimize time to market. The Warner Babcock Institute for Green Chemistry was founded in 2007 by Dr. John C. Warner, one of the founders of the field and co-author of seminal book Green Chemistry: Theory and Practice, which first defined the Twelve Principles of Green Chemistry.
Independent Beachbody Coach is a Wilsonville, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.